Dougan-Niklason House will be part of the new Campus North Residential Commons, scheduled to open at the start of the 2016–17 academic year.

Brady W. Dougan and Laura E. Niklason House

Dougan-Niklason House is named for University trustee Brady W. Dougan, AB’81, MBA’82, and Laura E. Niklason, PhD’88. Longtime supporters of the College and the University, they have provided support for the New Leaders Odyssey Scholarship, Jeff Metcalf Internship, and UChicago Careers in Business programs, as well as the Institute for Molecular Engineering and the University’s new Center in Hong Kong.

Brady graduated from the College, where he participated in the professional option program then offered, which allowed students to complete both their BA and MBA in five years. After starting his career in derivatives at Bankers Trust, he joined Credit Suisse, where he worked for 25 years. Widely recognized for his work ethic, which the New York Times has called “legendary,” Brady was the “youngest CEO on Wall Street” when he took over Credit Suisse’s investment bank in 2004, and in 2007 he became the first American to serve as Credit Suisse’s chief executive officer, a post he held until 2015. In addition to his finance pursuits, he has become a biotechnology investor, investing in and serving on the board of Humacyte, a regenerative medical technology firm founded by Laura in 2004, and investing in and serving as chairman of Regenovation, an early-stage regenerative medicine company focusing on cartilage regeneration.

Laura, who earned her PhD at the University in biophysics and theoretical biology and her MD from the University of Michigan, was a resident at Massachusetts General Hospital in Boston. There she joined Robert Langer’s lab at MIT and began her pioneering career in regenerative medicine. A professor of anesthesiology and biomedical engineering at Yale University, Laura focuses on vascular and lung engineering, including implantable arteries created from human tissue and cellular scaffolds designed to support lung regeneration. She is the founder of Humacyte, included in CNBC’s 2016 Disruptor 50 list of most innovative companies. At UChicago, Laura serves on the Visiting Committee to the Institute for Molecular Engineering.

“Laura and I owe much of what we have achieved to the unique and invaluable foundation provided by the University of Chicago,” Brady says. “That foundation was provided by the generosity of those who came before us, and we have been grateful to be able to contribute something back to the University and the College—it is particularly gratifying given the great progress and momentum of the school. We hope our sponsorship helps contribute to the success of those who come after us.”